Table 3. Main results of meta-analysis for the drug type and treatment length subgroups.
| N of cases | Heterogeneity analysis | Pooled SMD | 95% CI | ||
|---|---|---|---|---|---|
| I2 (%) | P value | ||||
| Pravastatin | 23 | 37 | 0.20 | 0.46 | -0.05-0.97 |
| Simvastatin | 206 | 24 | 0.26 | -0.12 | -0.28-0.04 |
| Simvastatin* | 115 | 0 | 0.71 | -0.26 | -0.47- -0.05 |
| Length of time required for medicine to be effective (≤1 month) | 145 | 54 | 0.04 | 0.05 | -0.14-0.24 |
| Length of time required for medicine to be effective (>1 month) | 381 | 1 | 0.42 | 0.02 | -0.10-0.14 |
*The data by Bailey et al. [12] were excluded. If P>1, there is no heterogeneity in simvastin subgroup.
Abbreviations: SMD, standard mean difference; CI, confidence interval.